Plain-English translation of NCT05797493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The PICASSO study is collecting detailed information—including blood samples, genetic material, and clinical data—from people with extensive-stage small cell lung cancer who have already received chemotherapy combined with anti-PD1/PD-L1 immunotherapy. Researchers want to understand how individual immune responses and tumor characteristics predict how well patients respond to treatment and survive.
Small cell lung cancer is aggressive, and doctors need better ways to predict which patients will benefit most from immunotherapy. This study explores new blood tests and immune markers that could one day help personalize treatment decisions and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would visit the study center to provide blood samples and allow researchers to review your medical records and tumor characteristics. The researchers will analyze your blood for immune cells, antibodies, and genetic markers, and combine this with information about how you responded to your chemotherapy and immunotherapy. You would be followed over time to see how these markers correlate with your treatment outcomes.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
Italy